Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
Casey Fazer, PA-C
Mayo Clinic, Rochester, Minnesota
Author’s disclosures of conflicts of interest are found at the end of this article.
Casey Fazer, PA-C, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905. E-mail: email@example.com
J Adv Pract Oncol 2019;10(suppl 1):37–46 |
© 2019 Harborside™
This article is a part of a JADPRO certified supplement, Immuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events
Table of Contents
- Immuno-Oncology Essentials: An Overview
- Meeting the Challenge of Immune-Related Adverse Events With Optimized Telephone Triage and Dedicated Oncology Acute Care
- PD-1/PD-L1 Inhibitors for Non–Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
- Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management (current article)
- Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types
- Appendix: Care Step Pathway Tools for Immune-Related Adverse Event Assessment and Management
Note: A typographical error has been corrected on page 41, where the starting thyroid replacement dosage should have been 1 to 1.6 μg/kg/day rather than 1 to 1.6 mg/kg/day. This has been corrected.
The introduction of immunotherapy to treat recurrent/metastatic head and neck squamous cell carcinoma in 2016 has provided new valuable treatment options to many cancer patients. Pembrolizumab and nivolumab, which are classified as immune checkpoint inhibitors of programmed cell death protein 1, have shown clinically significant activity in patients who progressed on or after platinum-based regimens, and these agents are now US Food and Drug Administration approved for this indication. These treatments can result in unique immune-related adverse events (irAEs) that many health-care providers have difficulty identifying and managing. This article addresses the important role advanced practice providers play in a care team. Their experience is vital to managing the irAEs that can occur in patients being treated with immunotherapy agents. Their early experience with these newer therapies allows them to help educate and support not only patients but other health-care providers as well. The Care Step Pathways (CSPs) created as part of the Immuno-Oncology Essentials initiative are excellent tools to help with the diagnosis and management of many irAEs. This article summarizes the CSPs on specific considerations when managing thyroiditis, mucositis/xerostomia, skin toxicities, and hepatotoxicity, and addresses the special concerns of the head and neck squamous cell carcinoma population.
How to Earn Credit
To qualify for CE credit, you must read all 6 articles in this supplement. To access the learning assessment and evaluation form online, visit https://education.annenberg.net/5686
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.
For access to the full length article, please sign in